Top 10 Life Science VC Funds in Italy

Last updated: Aug 2024 A list of 10 VC funds that invest in Life science startups based in Italy. We rank investors based on the number of investments they made in Life science companies from Italy. We update this investor list every month.

Top 10 Life Science VC Funds in Italy

Investor	Life Science Italy investments
Sofinnova Partners	4
Indaco Venture Partners	2
Principia SGR	2
Claris Ventures	1
Roche Venture Fund	1
Italian Angels for Growth	1
Club degli Investitori	1
Invitalia Ventures	1
JDRF T1D Fund	1
AbbVie Biotech Ventures	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

deepc — The Radiology AI Platform - Your effortless access to AI
Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Italy, Switzerland, United States

Portfolio highlights

Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
MicThera — MicThera focuses on developing microbial-derived therapeutics to provide effective treatments for prostate cancer patients, aiming to find effective solutions for medical companies.
Easy Rain — We are Easyrain. Continuous innovation runs in our blood.With our expertise, we develop, simulate, and test solutions, launching our ideas into production. We exploit the basic laws of physics to engineer a tangible solution!

Principia is an Italian Venture Capital firm with over Eur 80M under management. Currently Principia has two funds investing in digital start ups and expansion capital opportunities and in particular cases, we invest also in seed opportunities.

Investment focus

Health Care, Biotechnology, Software
Funding Round, Series A, Seed
Italy, United States, United Kingdom

Portfolio highlights

KLISBio — KLISBio is a medtech company currently developing a variety of regenerative medicine implantable products leveraging the power of silk fibroin to promote an endogenous repair of human soft tissues.
ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
WISE — WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

Claris Ventures is a venture capital firm supporting the best scientists in building successful life sciences companies that will impact people's lives

Investment focus

Biotechnology, Health Care, Therapeutics
Seed, Series A, Series B
Italy, United Kingdom

Portfolio highlights

NeoPhore — NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
ALKemist Bio — ALKemist Bio provides cell treatment to cancer patients.
Repron Therapeutics — Repron Therapeutics provides treatments for solid tumor cases where radical excision is not possible and metastasis or recurrence is extremely likely.

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

IAG is an angel investor network that offers access to its affiliates to early-stage venture opportunities. Its members to date have deployed over 22 million Euros to support 41 startups in the series seed/series A stage in many verticals, among which: Medtech, SAAS, e-commerce, Fintech, and high tech at large. Every investment opportunityat IAG is vetted by a professional team together with expert members of the group. Once invested, the company receives the support of up to two Investment champions, who bring their expertise to the table and help them succeed.

Investment focus

Software, E-Commerce, Health Care
Seed, Angel, Series A
Italy, United States, United Kingdom

Portfolio highlights

ALKemist Bio — ALKemist Bio provides cell treatment to cancer patients.
Rubedo Life Sciences — Rubedo Life Sciences is the Premier Longevity Company. Rubedo discovers and develops medicines to keep you biologically young.
Clearbox AI — Benefit from Synthetic Data to unlock your AI projects, overcome privacy issues and improve the utility of your data.

Club degli Investitori (Investors Club) is a network of investors and business angels that invest on early-stage SMEs and startups. The community of 300+ Members (entrepreneurs, CEOs, executive managers) actively scouts for investing opportunities on SMEs & startups and invests with a minimum ticket of €200k. The Club supports business byinvesting capital and by leveraging the Members' network and experience.Club degli Investitori is supported by Unicredit and KPMG Italy.

Investment focus

E-Commerce, Health Care, Software
Seed, Series A, Funding Round
Italy, United Kingdom, Israel

Portfolio highlights

Glaut — Glaut is an AI-native customer survey platform that conducts in-depth, AI-moderated interviews with customers at scale.
Algor Education — Algor Lab is a company that provides tools and materials needed for teaching through artificial intelligence.
ALKemist Bio — ALKemist Bio provides cell treatment to cancer patients.

Invitalia Ventures SGR manages the “Italia Venture Fund I”, a 87€/Ml sized co-investment fund that invests in early stage operations in Italy. They co-invest up to a maximum of 70% in round A (€ 0.5ML - € 1.5ML) in high growth sectors. Invitalia Ventures, with its network of co-investors not only provides risk capital, but also know-how and anetwork for business development. Main LPs includes the Ministery of Economic Development, the European Investment Bank, Cisco Group, the Sardinian Banking Foundation and Metec Group.They are looking for visionary entrepreneurs who share their passion for innovation. Growth is their mission!!For more information please contact us at info@invitaliaventures.it or visit our website: www.invitaliaventures.it

Investment focus

Software, Medical, Health Care
Series A, Funding Round, Seed
Italy, United States, United Kingdom

Portfolio highlights

Ecomate — The ESG Rating platform for every company
BigProfiles — A deep understanding of customers let a company tailor marketing campaigns and CRM strategies, but companies have only basic data about customers (e.g. gender or age). External data sources like Social Networks, Public Registries and Socio-Demographic data contain rich information about billions of people, like job titles, levels of education,interests and habits.BigProfiles is a Customer Intelligence SAAS that leverages external information about persons to enrich customer profiling: it can profile a company's customers with previously unknown information about them. Thanks to its Identity Resolution algorithm (the result of a PHD), it identifies a person’s information scattered among external sources.Through this technology, BigProfiles provides customer base analytics and behavior predictions: using Artificial Intelligence on enriched profiles allows to predict churn, fraud and willingness to buy.
Codemotion — Codemotion is the ecosystem devoted to innovation, focused on developers and coding, open to all programming languages and technologies. Pioneering spirits, it scout the future to deliver a first class experience to our people. Codemotion is one of the biggest tech-conferences in Europe, with an international network of 30.000 developers and 350speakers coming from all over the world and from the most important IT realities.Codemotion draw in its main conferences, thousands of attendees eager to discuss about hottest topics: it tailor for them disruptive proposals ranging from mobile to UX, develops, cloud, big data, gamedev, security, methods, languages, web, Internet of things. Codemotion is also a startup, providing a bunch of services and activities, for personal and business customers.

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
United States, France, Italy

Portfolio highlights

vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
Cour Pharmaceuticals Development — COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance...

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.